Type 2 Diabetes Mellitus

Inclusion Criteria

- Newly diagnosed T2DM (diagnosed within last 3 to 6 months) patient eligible for dual therapy exhibiting HbA1c is ≥ 7.5% to 9.0% will be enrolled after decision to administer acarbose/metformin fixed dose combination for type-2 diabetes management has been made by the attending physician on the basis of best clinical practice and patient needs. 
- Decision to initiate treatment with Acarbose/Metformin FDC was made as per Investigator’s routine treatment practice 
- Signed informed consent 
- No participation in an investigational program with interventions outside of routine clinical practice 
- No contra-indications according to the local prescribing information of GlucobayM

Exclusion Criteria

- Patients receiving any other anti-diabetic medication than the study drug at the time of enrollment in the study will be excluded. However, during observation period, any additional anti-diabetics medication administered by the attending physician will be acceptable & recorded in case record form. 
- Patients with type 1 diabetes 
- Patients with HbA1c > 9% 
- Patients who have serious infection, or have severe trauma 
- Patients who are pregnant or breast-feeding, or have the potential to become pregnant and child bearing female patients who are not willing to use any birth control measures
- All contra-indications according to the local marketing authorization should be considered 
- Patients with HbA1c with >9.0%: The target patient population is selected based on the AACE guideline recommendation to use combination therapy in case of higher glycaemia (HbA1c ≥7.5% - 9.0%) presented on diagnosis and also it is the common practice observed in India of using combination therapy in this group of patient as an initial therapy.